Seventeen individuals involved in a COVID-19 pandemic unemployment benefit scheme have learned their punishment.

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial ...

Surf Coast residents remain in the dark as to who their newest councillor is after the state’s electoral body encountered “technical difficulties” while trying to stage a countback.

The 2025 Autumn Fair in Hanoi has attracted large crowds over one week, with the cinema zone emerging as a major cultural ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.

Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

Trailing total returns as of 20/10/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) Return VEC-H.V S&P/TSX Composite index (^GSPTSE) ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks ...